SCHEMBL31015461

SCHEMBL31015461

Nc1cncc(C2CCCC2)n1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 9/20 0.42
CDK2 P24941 1/20 0.40
TDO2 P48775 2/20 0.37
PIK3CA P42336 1/20 0.36
FEN1 P39748 1/20 0.36
ATR Q13535 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
BACE1 P56817 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
SCN5A Q14524 1/20 0.35
SCN9A Q15858 1/20 0.35
NPC1 O15118 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
PKM P14618 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10010206 0.91 CDK2 (0.43) HRH4CDK2PIK3CAFEN1SCN5A
SCHEMBL11678872 0.75 ATR (0.35) HRH4ATRL3MBTL1
SCHEMBL11678522 0.75 CDK2 (0.40) HRH4CDK2ATRL3MBTL1NPC1
SCHEMBL19280323 0.74 PIM1 (0.33) L3MBTL1
SCHEMBL19626478 0.73 L3MBTL1 (0.38) HRH4ATRL3MBTL1NPC1RAB9A
SCHEMBL11684112 0.73 CDK2 (0.39) HRH4CDK2TDO2ATRL3MBTL1
SCHEMBL11677872 0.73 L3MBTL1 (0.38) HRH4TDO2FEN1ATRL3MBTL1
SCHEMBL19510671 0.71 CDK2 (0.40) HRH4CDK2L3MBTL1
SCHEMBL19625290 0.69 HMGCR (0.40) HRH4ATRL3MBTL1NPC1RAB9A
SCHEMBL21988030 0.69 HTR1A (0.46) HRH4BACE1NPC1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2025-01-02 US disclosed
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors EPICS THERAPEUTICS (BE) 2024-09-17 US disclosed
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2024-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 HRH4 1985/4885CDK2 838/4885TDO2 1933/4885
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 HRH4 1985/4885CDK2 838/4885TDO2 1933/4885
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors METTL3, METTL16, DIMT1 HRH4 1985/4885CDK2 838/4885TDO2 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.